Definium CFO granted 62,500 performance shares

Roberts Brandi reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Roberts Brandi reported acquisition or exercise transactions in this Form 4 filing.

Definium Therapeutics, Inc. Chief Financial Officer Brandi Roberts reported an equity compensation grant of 62,500 common shares at a price of $0.00 per share. These shares represent the first tranche of performance share units granted effective June 2, 2025.

The units remain subject to vesting based on her continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones in the Performance Share Unit Award Agreement. Following this award, Roberts directly holds 212,500 common shares.

Insider Trade Summary

Grant/Award: 62,500 shares

Grant/Award 1 txn

Insider Roberts Brandi

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	62,500	$0.00	$0.00

Holdings After Transaction: Common Shares — 212,500 shares (Direct)

Footnotes (1)

1. F1. The common shares represent the first tranche of performance share units granted effective June 2, 2025, and remain subject to vesting based on the Reporting Person's continued employment through June 2, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.

Key Figures

Shares granted: 62,500 shares Grant price: $0.00 per share Shares after transaction: 212,500 shares +2 more

5 metrics

Shares granted 62,500 shares Performance share unit grant effective June 2, 2025

Grant price $0.00 per share Equity compensation, no cash paid by CFO

Shares after transaction 212,500 shares Direct holdings following the grant

Vesting end date June 2, 2028 Continued employment requirement for vesting

Grant effective date June 2, 2025 Performance share unit award effective date

Key Terms

performance share units, vesting, clinical and regulatory milestones, Performance Share Unit Award Agreement

4 terms

performance share units financial

"The common shares represent the first tranche of performance share units granted effective June 2, 2025"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

vesting financial

"and remain subject to vesting based on the Reporting Person's continued employment through June 2, 2028"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

clinical and regulatory milestones financial

"subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement"

Clinical and regulatory milestones are the key steps a medical product must clear as it is tested on patients and reviewed by government health authorities, such as completing major clinical trials, filing safety and effectiveness data, or receiving marketing approval. Investors watch these checkpoints like milestones on a roadmap because each one sharply changes the odds that a product will reach patients and generate revenue, much like a car passing inspection before it can be sold.

Performance Share Unit Award Agreement financial

"milestones set forth in the Performance Share Unit Award Agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Definium Therapeutics (DFTX) report for its CFO?

Definium Therapeutics reported that CFO Brandi Roberts received a grant of 62,500 common shares as part of a performance share unit award. The shares were granted at $0.00 per share and increase her direct holdings to 212,500 common shares after the transaction.

How many Definium Therapeutics (DFTX) shares does the CFO hold after this Form 4?

After this grant, CFO Brandi Roberts directly holds 212,500 common shares of Definium Therapeutics. The 62,500-share award came through performance share units, granted at no cash cost, and remains subject to vesting conditions tied to continued employment and specific clinical and regulatory milestones.

What are the vesting conditions on the DFTX performance share units granted to the CFO?

The 62,500 performance share units will vest only if Brandi Roberts remains employed through June 2, 2028 and certain clinical and regulatory milestones are achieved. Each vested unit entitles her to receive one common share under the Performance Share Unit Award Agreement terms.

When were the Definium Therapeutics (DFTX) performance share units to the CFO granted?

The performance share units underlying the 62,500 common shares were granted effective June 2, 2025. They form the first tranche of that award and are subject to time-based vesting through June 2, 2028 and achievement of specified clinical and regulatory milestones before shares are fully earned.

Did the Definium Therapeutics (DFTX) CFO buy these shares on the market?

No, the CFO did not buy these shares on the open market. The Form 4 shows a grant classified as a performance share unit award at a price of $0.00 per share, reflecting equity compensation rather than a purchase transaction or open-market investment decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 09:45 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts Brandi

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NEW YORK 10007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/22/2026		A		62,500(1)	A	$0.00	212,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The common shares represent the first tranche of performance share units granted effective June 2, 2025, and remain subject to vesting based on the Reporting Person's continued employment through June 2, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.

	/s/ Mark Sullivan, Attorney-in-Fact for Brandi Roberts	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)